Home » Stocks » BIO

Bio-Rad Laboratories, Inc. (BIO)

Class A Shares
Stock Price: $584.50 USD 2.05 (0.35%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 17.53B
Revenue (ttm) 2.55B
Net Income (ttm) 3.81B
Shares Out 29.77M
EPS (ttm) 126.20
PE Ratio 4.63
Forward PE 49.26
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $584.50
Previous Close $582.45
Change ($) 2.05
Change (%) 0.35%
Day's Open 588.60
Day's Range 578.00 - 592.94
Day's Volume 242,319
52-Week Range 309.38 - 689.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Forbes - 2 days ago

Non-operating income not only overstates GAAP net income but could negatively impact Bio-Rad's ability to obtain additional financing.

Business Wire - 6 days ago

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwa...

Zacks Investment Research - 6 days ago

Does Bio-Rad Laboratories (BIO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 2 weeks ago

Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

Zacks Investment Research - 2 weeks ago

Bio-Rad (BIO) delivered earnings and revenue surprises of 29.35% and 15.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 weeks ago

Shares of Bio-Rad Laboratories (NYSE:BIO) moved higher by 2.0% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 72.84% year over ye...

Business Wire - 2 weeks ago

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results...

Benzinga - 2 weeks ago

Bio-Rad Laboratories (NYSE:BIO) unveils its next round of earnings this Thursday, February 11. Get prepared with Benzinga's ultimate preview for Bio-Rad Laboratories's Q4 earnings.

Zacks Investment Research - 3 weeks ago

Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.

Investopedia - 1 month ago

These are the stocks with the best value, fastest growth, and most momentum for February.

Other stocks mentioned: AGCO, BDN, BPYU, ENPH, MRNA, NLOK, NRG, PTON, ROK, TSLA, UNVR, XRX, ZM
Business Wire - 1 month ago

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for...

Investopedia - 1 month ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Other stocks mentioned: BIIB, CVS, HZNP, MRNA, PODD, QDEL, TDOC
GuruFocus - 1 month ago

If you pick securities whose earnings return is more than twice that of the 20-year high-quality market corporate bonds, you could increase your probability to unearth value opportunities, in ...

Other stocks mentioned: FVE, SUPN
Business Wire - 1 month ago

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwa...

GuruFocus - 1 month ago

"Why do you like tobacco stocks so much?" my colleague asked our boss, David Dreman (Trades, Portfolio), about two decades ago.

Other stocks mentioned: AEL, CNNE, FF, IMKTA, REGI, UNM, WOR, HUN, PDM
Investopedia - 2 months ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Other stocks mentioned: BIIB, CVS, HZNP, MRNA, PODD, QDEL, XLRN, XLV
GuruFocus - 2 months ago

Perhaps you've seen the Energizer Bunny in a battery commercial. It is "still going" long after you'd expect it to fade.

Other stocks mentioned: EQC, FFWM, LGIH, MSBF, MSGN, PFSI
Business Wire - 2 months ago

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today its outlook throu...

Zacks Investment Research - 3 months ago

Investors continue to be optimistic about Bio-Rad (BIO) on robust growth of the Life Science segment and a solid testing portfolio.

Investopedia - 3 months ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.

Other stocks mentioned: PODD, XLV, MRNA
Zacks Investment Research - 3 months ago

Is (BIO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 3 months ago

Top Ranked Momentum Stocks to Buy for November 13th

Other stocks mentioned: PLT, SSTK, THRM
GuruFocus - 3 months ago

Value focused investors may want to consider the following stocks, since their share prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based discounted ...

Other stocks mentioned: BK, GLIBA
Zacks Investment Research - 3 months ago

As of late, it has definitely been a great time to be an investor in Bio-Rad Laboratories (BIO).

Zacks Investment Research - 3 months ago

Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research - 4 months ago

Bio-Rad's (BIO) third-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

Seeking Alpha - 4 months ago

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Bio-Rad (BIO) delivered earnings and revenue surprises of 62.16% and 14.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 months ago

Shares of Bio-Rad Laboratories (NYSE:BIO) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 86.34% year over year to $3.00, whi...

Business Wire - 4 months ago

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results...

Insider Monkey - 4 months ago

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...

Zacks Investment Research - 4 months ago

Bio-Rad (BIO) Q3 earnings are expected to have benefited from strong sales particularly within core PCR products, Droplet Digital PCR and Process Media.

Zacks Investment Research - 4 months ago

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 4 months ago

Bio-Rad Gains 16.2% Since September, Bullish Outlook Remains Strong

Business Wire - 4 months ago

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for...

Zacks Investment Research - 4 months ago

Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.

GuruFocus - 5 months ago

With four potential Covid-19 vaccine candidates from Moderna Inc. (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), AstraZeneca PLC (NYSE:AZN) and Johnson & Johnson (NYSE:JNJ) now in late-stage human tri...

Other stocks mentioned: DVA, MOH
Investopedia - 5 months ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

Other stocks mentioned: BIIB, CVS, IMMU, LVGO, MRNA, PODD, PRGO, QDEL
Zacks Investment Research - 6 months ago

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 6 months ago

Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.

Other stocks mentioned: ABMD, DHR, DXCM, HOLX, IDXX, REGN, TMO, VRTX, WST
CNBC Television - 6 months ago

Jefferies' Steven Desanctis on why investors should look beyond Big Tech

Steven Desanctis, Jefferies U.S. small mid-cap strategist managing director, joins 'Power Lunch' to discuss why investors can look to invest in names beyond Big Tech.

Other stocks mentioned: A, BK, VIRT, EFX, LECO, PSN
Seeking Alpha - 6 months ago

FCF has grown 159% YoY, however ROCE remains sluggish at only 3%, which we feel needs evidence of improvement into Q3.

Zacks Investment Research - 6 months ago

Bio-Rad Laboratories (BIO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Investment Research - 6 months ago

Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Business Wire - 6 months ago

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the United States Court of Appeals for the Federal Ci...

Zacks Investment Research - 7 months ago

Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.

Zacks Investment Research - 7 months ago

Bio-Rad (BIO) delivered earnings and revenue surprises of 23.85% and 1.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 7 months ago

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc.

Zacks Investment Research - 7 months ago

Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.

Other stocks mentioned: BAX, QDEL, SYK, TFX
Zacks Investment Research - 7 months ago

Strength in product demand related to COVID-19 testing and research is likely to have aided Bio-Rad's (BIO) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

About BIO

Bio-Rad Laboratories develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques... [Read more...]

Industry
Medical Devices
Founded
1952
CEO
Norman Schwartz
Employees
8,000
Stock Exchange
NYSE
Ticker Symbol
BIO
Full Company Profile

Financial Performance

In 2020, BIO's revenue was $2.55 billion, an increase of 10.12% compared to the previous year's $2.31 billion. Earnings were $3.81 billion, an increase of 116.43%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is 752.50, which is an increase of 28.74% from the latest price.

Price Target
$752.50
(28.74% upside)
Analyst Consensus: Buy